NCT03341741View on ClinicalTrials.gov

Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 11, 2014

Primary Completion Date

December 19, 2015

Study Completion Date

November 25, 2016

Conditions
Cystic Fibrosis With Pulmonary Manifestations
Interventions
DRUG

Tobramycin Powder

TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);

DRUG

Colistin

Colistin solution 2 x daily 1 Mega continuously

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT03341741 - Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients | Biotech Hunter | Biotech Hunter